Payments processing company EML is looking at two potential shareholder class actions over its alleged failure to notify the market of concerns by Ireland’s central bank relating to compliance with anti-money laundering regulations.
The state of Victoria has opted out of two class actions over allegedly combustible cladding, after agreeing to join as a group member last year.
Unlike many successful litigation partners, Arnold Bloch Leibler partner Elyse Hilton wanted to be “anything but a lawyer” when she was in high school.
Federal politician Peter Dutton has been ordered into mediation in his defamation case against a refugee activist over a tweet calling the defence minister a “rape apologist”, with a judge saying the case could be settled without a trial.
Ben Roberts-Smith used burner phones to call SAS colleagues after growing fearful that members of the media were listening into his phone calls after a series of articles were published in 2018 that accused him of war crimes and domestic violence, a court has heard.
Industry super funds AustralianSuper and IFM Investors – the consortium behind the interest rate swap at the centre of the corporate watchdog’s insider trading case against Westpac — have asked a judge to shield commercially sensitive information from the public as the high-profile action unfolds.
A judge has overturned a ruling from the Australian Patent Office that shortened the amount of time available to companies under patent term extensions, saying a “liberal rather than literal” reading was needed to achieve the extension regime’s goals of compensating holders of drug patents for the lengthy time required to obtain regulatory approval to market their drugs.
Former Victoria Labor politician Adem Somyurek has hit Nine with a defamation lawsuit over a 60 Minutes segment and two articles that appeared in The Age that accused him of corruption and branch stacking and branded him the ‘factional kingpin’ of the Australian Labor Party.
Switzerland-based Biogen has sued generic drug maker MSN Laboratories for allegedly threatening to infringe the patent for its top-selling oral MS drug Tecfidera.
Tabcorp-owned Tatts Group has appealed a finding from the Commissioner of Taxation that it cannot deduct a $120 million lotto licence from it assessable income for the 2017 financial year.